OADR-ORWH Funding Information and Funding Opportunities

OADR-ORWH in Fiscal Year 2023

The funding strategy for the inaugural year of OADR-ORWH funding was based on recommendations from NIH institutes and centers (ICs), and diseases included in the autoimmune portfolio in the NASEM report. In FY23, OADR-ORWH supported a total of 41 awards across 12 individual ICs. This included 15 extramural co-funding awards, 3 R56 bridge funding awards, 2 Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) awards, 10 intramural co-funding awards, 5 intramural scientific fellowships, and 6 EXposome in Autoimmune Disease Collaborating Teams PLANning Awards (EXACT-PLAN). The EXACT-PLAN Notice of Special Interest (NOSI) (NOT-OD-23-112) was developed by OADR-ORWH in partnership with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Environmental Health Sciences (NIEHS), and NIH Institute, Center, and Office (ICO) partners. The EXACT-PLAN focuses on supporting the design, development, and implementation of a future national, interdisciplinary, collaborative, team science research network that will advance the study of the exposome in autoimmune disease. The funded awards spanned basic to translational science, clinical, and public health research focused on autoimmune disease.

See Figures a-c: Office of Autoimmune Disease Research (OADR-ORWH) Fiscal Year (FY) 2023 Funding Allocation by [a] Activity and [b-c] Administering Institute/Center.